医生向郑姨解释道，她们村的卫生室已纳入"星网计划"智慧化慢病管理网络，不仅配备了相应设备，村 医也都经过专业培训，检查数据能实时上传至上级医院。 据悉，星网计划着力构建"区域医疗中心—县域医院—中心医院—基层诊室"四级慢病管理网络。通过系 统培训与质量控制，实现慢病管理的上下贯通、横向协同、四级联动，彻底改变以往"单兵作战"的局 面。同时，该计划实现了"数据跑路、患者省心"，依托自主研发的多方互通数据平台，推动慢病管理与 数字技术深度融合。通过算法持续迭代，实现优质医疗资源广泛共享，构建覆盖"防—筛—诊—管—康 —教"的多病种、全流程闭环管理体系。换言之，借助医疗数字化平台、可穿戴设备、智能终端等先进 手段，居民居家即可自我监测，数据可实时上传与智能分析，大幅减少等待时间，提升医疗资源利用效 率。 此后，郑姨便定期带着老伴去村卫生室复查，步行仅几分钟，整个过程快捷方便。然而一周前，就在这 短短的路上，郑姨突然感到胸闷、胸痛。联想到自己十多年前曾有类似症状，她在老伴复查后，请村医 为自己也做了一次心电图。 截至目前，聚焦重大慢病防控的星网计划已完成医药高新区（高港区）13家镇街卫生院、93家村卫生室 100%智 ...

Core Insights - The Chinese gene testing industry is experiencing a shift from reproductive health to the "silver economy," driven by structural changes in the newborn population and an increasing elderly demographic [2][3] - BGI Genomics is strategically pivoting towards the silver economy, addressing a significant market gap in health management for the aging population [2][4] Market Size and Demand - By the end of 2024, the population aged 60 and above in China is projected to reach 310 million, with the silver economy market size estimated at approximately 7 trillion yuan in 2023, potentially growing to 19 trillion yuan by 2035 [3] - The focus of this market is shifting from traditional elder care to proactive health management, driven by a new generation of elderly consumers who are tech-savvy and financially capable [4][5] Structural Discrepancies in Healthcare - The traditional healthcare system has been centered on treatment rather than prevention, which is inadequate for managing chronic diseases prevalent among the elderly [5][6] - There is a growing demand for early risk warning systems and personalized management plans to enhance the quality of life for the aging population [5][7] Consumer Behavior - The market's payers include not only the elderly but also their adult children, who are increasingly purchasing digital health management services to care for their parents from a distance [6][7] BGI Genomics' Strategy - BGI Genomics is implementing a dual approach of "precise chronic disease management products" and "intelligent health management tools" to support proactive health management [9][14] - The company is focusing on high-incidence diseases among the elderly, such as Alzheimer's and cardiovascular diseases, with innovative testing solutions [10][11] Health Management Tools - The "i99 Smart Health" system by BGI Genomics serves as a health data translator and personal health advisor, providing understandable health management reports and actionable recommendations [12][13] - This system leverages extensive databases and AI capabilities to ensure that health advice is data-driven and scientifically supported [13][14] Overall Objective - The ultimate goal of BGI Genomics' strategy is to empower the elderly and their families with control over health management, transitioning from reactive to proactive care [16]

过去，中国慢病管理市场线上渗透进展缓慢。 慢性非传染性疾病带来的健康损害不可估量，是我国居民的最重要死因。随着人口老龄化进程不断加 快，慢性病疾病负担日益沉重。 "人口老龄化给医疗带来的压力，我们需要一种有效的缓解方法。"近日，在方舟健客第十届H2H医疗服 务生态大会上，方舟健客创始人、董事长兼首席执行官谢方敏说。 看病难、随访难、出行不便，是很多慢病管理面临的一些痛点。大模型的发展，正在重塑医疗行业，一 些互联网医疗平台也希望借助AI技术提速慢病管理业务发展。 有三甲医院医生对第一财经记者表示，在长期治疗中，影响慢病患者患者预后的主要就是如何管理问 题。过去采用传统方式，见面诊疗后鼓励患者前来复诊或到社区医院复诊，但很多患者症状改善后就不 再复诊。 这些年，不少互联网平台希望医生与慢病患者在线下完成首诊后，可以把复诊的场景搬到线上，但线上 问诊的难点是用户往往期待医生回复速度快、问诊质量高，而医生不可能一直在线上"蹲守"，回复不及 时，导致用户就医体验不理想。从过往看，中国慢病管理市场线上渗透进展缓慢。根据灼识咨询预测， 2023年，中国慢病管理市场线上渗透率为4.4%。 大模型的发展，让互联网医疗平台看到 ...

Core Insights - The number of internet hospitals in China reached 3,756 last year, with a total of 130 million patient visits, indicating significant growth in the sector [1][4] - The integration of AI technology has improved the efficiency of online consultations, allowing doctors to manage their time better and enhance patient care [3][6] - Companies like Ping An Good Doctor and JD Health reported profitability in the first half of this year, reflecting a positive trend in the internet healthcare industry [6] Group 1: Industry Growth - The internet healthcare sector has seen a surge in patient numbers, particularly among chronic disease patients who benefit from online consultations [5][6] - The convenience of internet hospitals allows patients to send medical reports in advance, reducing the need for travel to major cities for consultations [1][3] Group 2: AI Integration - AI technology is being utilized to streamline the online consultation process, with platforms providing "personal AI assistants" to help doctors prepare for patient interactions [3][6] - The use of AI has reportedly increased service efficiency by 33%, saving doctors approximately 60,000 hours of work [3] Group 3: Chronic Disease Management - Chronic disease management is a key focus for internet hospitals, with platforms enhancing patient adherence to treatment through reminders and follow-ups [6][7] - The ability to provide medication delivery services is particularly beneficial for patients in remote areas, improving access to necessary treatments [3][6]

Core Insights - Diabetes is a global public health challenge, with over 500 million patients worldwide, predominantly suffering from type 2 diabetes. China faces a significant burden in diabetes management [1] - Eli Lilly's ACHIEVE-3 study provides new insights into managing type 2 diabetes, comparing orforglipron and oral semaglutide, showing orforglipron's superior efficacy in reducing A1C levels and weight loss [1][2] - The study indicates that orforglipron leads to a 2.2% reduction in A1C levels compared to 1.4% for oral semaglutide, and participants on orforglipron lost an average of 8.9 kg (9.2%) versus 5.0 kg (5.3%) for semaglutide [1][2] Group 1 - Orforglipron shows significant improvements in cardiovascular risk factors, including non-HDL cholesterol, systolic blood pressure, and triglycerides, while maintaining safety and tolerability [2] - The research expands chronic disease management pathways, providing more tools for personalized treatment plans, which is crucial for long-term diabetes management [2] - The ATTAIN-1 study also demonstrated that orforglipron can aid in weight loss and improve cardiovascular risk factors in overweight or obese individuals without diabetes [2] Group 2 - Eli Lilly emphasizes the importance of convenient medication options for early management of metabolic disorders, shifting the focus from treatment to prevention [3] - The company is advancing orforglipron's application for obesity treatment globally, with regulatory approval expected soon, while the application for type 2 diabetes treatment is anticipated in 2026 [3] - The innovation in drug development is expected to translate into accessible health benefits for the public, contributing to overall health goals [3]

9月16日，国新健康保障服务集团股份有限公司以电话会议形式召开业绩说明会，地点位于北京市东城 区沙滩后街22号院2号楼、3号楼。参与此次会议的有中国证券报、上海证券报等多家新闻媒体单位，以 及华泰证券、国联民生证券等超50家机构及个人投资者。公司党委副书记、董事、总经理袁洪泉，独立 董事孙娜，副总经理、总法律顾问、首席合规官周蔚，党委委员、总会计师王文长，董事会秘书刘新星 出席会议。 会上，总经理袁洪泉介绍了2025年半年度经营情况，并对未来工作进行展望；总会计师王文长汇报了 2025年半年度财务数据。随后的互动交流环节，投资者就公司AI应用、健康险业务、各板块业绩增长 等多方面进行提问，公司领导一一解答。 数字医药业务增长可期 公司数字医药业务上半年收入高增长，毛利率提升。因业务成本主要为人工成本且相对固定，收入增加 带动毛利率上升。业务从药械智慧监管向药企数字化服务拓展，市场空间广阔，有望持续增长。 AI应用广泛，助力业绩提升 投资者关注到公司上半年设立AI中心，推出相关模型和平台，询问AI应用及商业化情况、对业务的赋 能、对订单和业绩的影响，以及中长期战略规划。公司回应称，AI已在医保、医疗、医药等多领 ...

9月10日，方舟健客第十届 H2H 医疗服务生态大会在上海举办。会上，方舟健客（06086）重磅发布了 公司自主研发的"慢病管理数智之芯"——杏石医疗大模型。这一重磅发布，不仅是方舟健客对国家"人 工智能+"行动的积极响应，更是为破解"传统慢病管理效率低"、"服务精准度不足"、"医生碎片化时间 难利用"等行业核心难题提供了突破性的技术解决方案，有望成为驱动"AI+慢病管理"领域全面升级的核 心技术底座。 在现场演示环节中，使用者只需通过语音输入需求口令，如 "解读 2024 年修订版高血压指南，核心对 比与 2018年修订版高血压指南的区别"，杏石 AI 学术助手就能搜索匹配相关信息，高效生成对比报告 并完成实时语音播报。有一线专家在了解后评价道："分析能力、推理能力、理解能力都让人惊喜，杏 石AI学术助手或能成为临床医生的'声纹级医学大脑'。" 作为公司的"超级数字大脑"和"强大智慧中枢"，杏石医疗大模型首先构建了图像语音识别、自然语言理 解、海量医药知识存储及推理思考的底层能力体系。其次，凭借其达到SOTA（State-of-the-Art）水平的 医疗领域大模型性能，它还将知识、导诊、预问诊、医生、电子 ...

Core Insights - The core message emphasizes the need for a systemic approach to chronic disease management, moving away from fragmented treatments to comprehensive care solutions for patients with cardiovascular diseases and diabetes [1][2] Group 1: Disease Statistics and Impact - As of 2023, there are 578 million diabetes patients globally, with 233 million in China, indicating that 1 in 6 Chinese individuals is affected, and 34.6% of these patients are at risk of diabetic retinopathy [1] - The number of cardiovascular disease patients in China has reached 330 million, with 2 out of 5 deaths attributed to myocardial infarction, stroke, and heart failure [1] Group 2: Challenges in Current Treatment Approaches - Clinical data shows that 59.8% of diabetes patients also suffer from coronary heart disease or diabetic retinopathy, requiring an average of 4.3 medications daily, leading to a medical expenditure 2.7 times higher than that of the general population [2] - The median secondary prevention period for coronary heart disease patients in China is only 5.2 months, which is less than half of the duration recommended by international guidelines [2] Group 3: Innovative Solutions by the Company - The company introduces a comprehensive management solution for chronic disease patients, focusing on both medication and diagnostic tools, such as the compound Danshen dripping pill, which has dual mechanisms for treating diabetic retinopathy [3][6] - The "Heart Protection" project aims to address the increasing incidence of cardiovascular diseases in China, which is growing at 5% annually, and aims to implement the "Healthy China 2030" strategy into actionable solutions [3][4] Group 4: Community and Grassroots Initiatives - The company collaborates with the China Medical Education Association to launch the "Heart Power - Rewalk the Long March" initiative, which includes free clinics and training for grassroots healthcare providers, enhancing awareness and early screening for diabetes [5] - The initiative has reached 16 cities across China, emphasizing the importance of community engagement in chronic disease management [5] Group 5: Product Innovation and Market Position - The company’s compound Danshen dripping pill has been recognized as a leading brand in heart disease treatment and has expanded its indications to include diabetic retinopathy, showcasing its commitment to innovation [6][7] - The company maintains a robust pipeline of 83 products under development, including those targeting women's and rare diseases, ensuring a diverse range of treatment options [11] Group 6: Corporate Social Responsibility and ESG Practices - The company integrates its healthcare solutions with social responsibility initiatives, participating in various public welfare activities and maintaining a commitment to sustainable development [10][12] - The "Heart Power" initiative has received multiple awards for its contributions to social responsibility, highlighting the company's dedication to community health [10]

Core Insights - The article highlights Ark Health's impressive mid-year performance for 2025, showcasing strong revenue growth and profitability, while aligning with the trends in AI and chronic disease management [1][2]. Financial Performance - Ark Health reported revenue of approximately 1.494 billion RMB, a year-on-year increase of 12.9%, indicating robust business expansion despite a slowing growth rate in the internet healthcare sector [2]. - The company achieved a net profit of around 12.5 million RMB, marking a turnaround from losses, with adjusted net profit rising 16.8% year-on-year to approximately 17.6 million RMB, setting a historical high [2]. - Registered users reached 52.8 million, a 15.8% increase, while monthly active users surged to 11.9 million, reflecting a significant 34.4% growth [2]. User Engagement and Ecosystem - The company boasts a high repurchase rate of 85.4% among paying users, with prescription drug transactions accounting for 81.7%, reinforcing its focus on chronic disease management [3]. - Ark Health has established partnerships with over 1,650 suppliers and more than 980 pharmaceutical companies, expanding its drug SKU to 216,000, with approximately 62% being prescription drugs [3]. AI Integration and Competitive Advantage - The integration of AI technologies has enhanced Ark Health's service offerings, including the development of AI-driven solutions for patient management and medical record keeping [5][6]. - The "familiar doctor-patient" model differentiates Ark Health from competitors, fostering long-term relationships that enhance user loyalty and engagement [4][6]. Market Trends and Growth Potential - The AI and healthcare sector is experiencing significant growth, driven by policy support and increasing demand for efficient chronic disease management services [7][8]. - The digital chronic disease management market in China is projected to grow from 113.7 billion RMB in 2019 to 464.5 billion RMB in 2023, with a compound annual growth rate of 42.2% [8]. Future Outlook - Ark Health's AI-driven chronic disease management solutions are expected to expand further, capitalizing on the ongoing digital transformation in primary healthcare [10]. - The company's current market valuation does not reflect its growth potential, with a significant upside projected based on its performance and market trends [11].

Core Viewpoint - The pharmaceutical retail industry is experiencing a period of adjustment, yet Dazhonglin (603233.SH) demonstrates resilience with double-digit growth in performance, particularly in the second quarter of 2025, despite a challenging market environment [1][2]. Financial Performance - In the first half of 2025, Dazhonglin achieved operating revenue of 13.522 billion yuan, a year-on-year increase of 1.33%, while net profit attributable to shareholders reached 798 million yuan, up 21.38% year-on-year [1]. - The second quarter of 2025 saw net profit of 359 million yuan, reflecting a significant year-on-year growth of 45.3%, indicating accelerated profit growth [1][2]. Industry Trends - The total number of pharmacies in China decreased by 0.5% at the end of 2024, marking the first quarterly decline in recent years, with the trend continuing into the first quarter of 2025 [2]. - The pharmaceutical retail industry is undergoing accelerated consolidation, with increasing compliance costs leading to the exit of non-compliant pharmacies from the market [6]. Strategic Initiatives - Dazhonglin is focusing on three main areas: building a prescription acceptance system, accelerating the acquisition of medical insurance qualifications for stores, and enhancing professional service capabilities [3]. - The company has established a 24-hour delivery service with a 93.54% coverage rate for its O2O delivery service, and has expanded its B2C operations using a multi-warehouse distribution model [2]. Market Positioning - Dazhonglin's store count increased by 280 in the first half of 2025, reaching a total of 16,833 stores across 21 provinces, showcasing its strong market presence [6]. - The company is leveraging a franchise model to enhance its market share, which is crucial for navigating the unique landscape of China's pharmaceutical retail sector [6][7]. Service Development - Dazhonglin is actively developing chronic disease management services, with a focus on enhancing the professional capabilities of its staff to meet the growing demand from an aging population [5]. - The company has trained over 170 pharmacists and more than 1,500 staff in chronic disease management, conducting over 100,000 health checks and 40,000 patient education sessions [5]. Competitive Landscape - The pharmaceutical retail industry is witnessing a "Matthew Effect," where larger companies like Dazhonglin are gaining market share at the expense of smaller players due to their scale and operational efficiency [6][7]. - As regulatory pressures increase, the competition is expected to favor larger, well-managed chains that can effectively navigate the complexities of the market [7].